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Sm Twenty patients with kloaly advanced or metastatic breast cancer were treated with four cydes of
ifosfamide/mesna 5 gm2 and epirubicn 60mg m-2 every 14 days with granulocyte colony-stimulating factor
(G-CSF, F-dgrastim). Complete remission occurred in six out of the 20 patients (301/., 95% confidence interval
12-54%) and there wer 12 partial (60%/, 95% confidence interval 37-81%), thus giving an
overall response rate of 90% (95% confidenee interval 63-97%). Two patients had progresve diseas. The
median duration of response for those patients with metatatic sea was 7.3 (1.3-20.1 +) months. The
median survival time for these patients was 15 (5.3-27.9+) months. Of the four patients treated with locally
advanced disea three achieved a complete cinil resonse and one a partial response. Three out of four of
these patients Subsequently underwent a mastectomy, and in one of these no viable tumour was seen. Our
conclusion is that this is exclent palliation for metastatic disea and possibly usefil neoadjuv.ant
treatment.
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Approximately 12 000 women in England and Wales die each
year from metastatic breast cancer. Despite the high
chemosensitivity of breast cancer, the disease is never curable
once it becomes metastatic (Fey et al., 1981; Paterson et al.,
1981). The median survival of patients with metastatic breast
cancer is about 2 years (Clark et al., 1987; Mick et al., 1989).
There is therefore a great need to improve the therapy of
metastatic breast cancer in order to make the responses more
durable.
Retrospective analysis of the dose of chemotherapy
received per unit time (dose intensity) has shown that there
has been a good correlation between dose intensity and
survival (Hryniuk and Bush, 1984). This has fuirther been
confirmed by two prospective randomised trials. The first by
CarmoPereira et al. (1987) compared two differing dose
intensities of doxorubicin in patients with advanced breast
cancer and demonstrated a survival advantage with the
higher dose intensity of doxorubicin. The second study, by
Tannock et al. (1988), compared two different schedules of
cyclophosphamide, methotrexate and 5-fluorouracil (CMF)
chemotherapy and demonstrated greater survival in the more
intensive arm. There are, however, a number of negative
studies showing no dose-response effect in the treatment of
advanced breast cancer (Tormey et al., 1982; Hortobagyi et
al., 1987). However, the actual differences in dose intensity in
these studies were rather minimal. Larg increases in the
intensity of conventional chemotherapy are limited by
myelosuppression. However, the advent of growth factors
into clnical practice has allowed the clinician largely to
prevent or ameliorate chemotherapy-induced neutropenia
(Bronchud et al., 1987). Furthermore, it has been possible to
use growth factors to accelerate the delivery ofchemotherapy
and escalate the doses of drugs used. Bronchud et al. (1989)
have used granulocyte colony-stimulating factor (G-CSF, Fil-
grasiim) to inrease both the frequency and dose of doxo-
rubicin delivered to patients with metastatic breast and
ovarian cancer. However, this approach is limited by the
development of severe muxosal and skin toxicity. In another
study using granulocyte-macrophage colony stimulating fac-
tor (GM-CSF), Hoek-man et al. (1991) gave high doses of
cyclophosphamide and doxorubicin to 18 patients with
advanced breast cancer and obtained an 89% objective re-
sponse rate. However, this was still attended by an
appreciable incidence of neutropenic sepsis and there was
considerable toxicity from the GM-CSF. We have previously
given ifosfamide and doxorubicin to patients with advanced
breast cancer and obtained very high response rates (Mill-
ward et al., 1990). In this study no growth factors were used
and cycles could only be admist at 21 day intervals. We
therefore decided to give four cycles of ifosfamide with
epirubicin every 14 days with daily subcutaneous injections
of G-CSF to women with metastatic or locally advanced
breast cancer in order to improve the response rate and
duration. It was decided to substitute epirubicin for doxo-
rubicin in order to reduce the risk ofcardiac problems as this
study was a prelude to a second study in which it was
planned to escalate the dose of anthacycline. Only four
cycles of treatment were planned as our previous study had
demonstrated that maximum response is generally achieved
after two cycles.
PateUs ad
Patients
Women with a histological diagnosis of breast cancer who
had metastatic or locally advanced disease that was evaluable
either dinially or by radiological methods were considered
eligible for inclusion. Patients had to be aged between 18 and
55 years and have a performance status of 0-2 (ECOG).
Before therapy patients had to have an absolute neutrophil
count of 2.0 x 1091-', a platelet count of > 100 x 109 1,
a creatinine clarance of 60mlmin-', a serum biiubin
<35 mmol 1' and a serum albumin within the normal range
of 35-50gl-1'. All patients had bidemensionally measurable
disease of at least 2 cm in diameter. Patients with bone
disease alone were not included. Repeat measurements were
made 1 month after the last cycle of chemotherapy. Patients
with cerebral metastases or marrow infiltration were
excluded. Prior treatment, except with non-anthracyclne-
containing chemotherapy in an adjuvant setting, was also an
exclusion criterion. Individuals with severe cardiovascular
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with endocrine agents was not allowed. Tberapy on relapse
was at the clinician's discretion but did not involve further
high-dose treatment.
Treatment
Patients were treated with epirubicin 60mgm-2 as a slow
intravenous injection. This was followed by 1 gm-2 mesna
given as an intravenous bolus. Subsequently 5 gm-2 ifos-
famide with 3 gml 2 in 31 of dextrose saline was infused
over 24h. A further 1gm2 mesna was infused in 11 of
dextrose saline over 8 h. Cycles were repeated every 14 days
to a maximum of four cycles unless there was disease pro-
gression. Recombinant metHuG-CSF (Filgrasfim, Amgen)
was adminstered by either the patient or distrit nurse at a
dose of 5jug kg-' subcutaneously once daily for days 3-13 of
each treatment cycle. If the absolute neutrophil count
reached a level of )20.0x 1091-l at any time after the
expected nadir, treatment with G-CSF was discontinued until
the next cycle of chemotherapy. If on the day of treatment
the absolute neutrophil count was <1.0 x l0 1-' or the
platelet count was <50 x l09 1' chemotherapy was delayed
for 7 days, and if the counts had not recovered to these klvels
by this time the patient went off study. Routine antiemetics
consisting of domperidone 30mg6 hourly, dexamethasone
4 mg 6 hourly and lorazepam 1 mg b.d. were administered to
all patients.
Clinical andlaboratory monitoring
During chemotherapy full blood count estimations were per-
formed at weekly intervals. Prior to the start of chemo-
therapy left ventricular function was asd using multiple
gated acquisition scan (MUGA) scans and this was repeated
after four cycles. Tumour response was assessed every cycle
using standard UICC (International Union Against Cancer)
criteria (Hayward et al., 1977).
Results
Response and survival
A total of 20 women with metastatic or locally advanced
breast cancer were treated with the above regimen. Seventeen
patients had metastatic disease and three had locally
advanced breast cancer. The median age of the patients
treated was 44 years (range 23-55 years). The details of these
patients are shown in Table I. There were six complete
remissions (CRs), giving a complete response rate of 30%
(95% confidence interval 12-54%), and 12 partial re-
sponders (PRs), giving a ptial response rate of 60% (95%
confidence interval 37-81%) and an objective response rate
of 90% (95% confidence interval 63-97%). Responses were
seen in both soft-tissue and visceral disease. Two patients
had progressive disease. Responses were seen in both locally
advanced and metastatic disease. The median duration of
response for those patients with metastatic dises was 7.3
(1.3-20.1 +) months and their median survival 15 (5.4-
27.9+) months. Five patients wtih locally advanced disease
were treated. Three out of four achieved a clinical complete
response and one a clinical partial response. Three out of
four went on to receive a mastectomy. In one mastectomy
specimen no viable tumour was seen. Two out of four of
these patients are currently alive and disease free 20+ and
27+ months later.
Toxicity
Haematological A total of 79 of a projected 80 courses of
chemotherapy were delivered. One course of chemotherapy
was not administered because of disease progression after
three cycles. No dosage reductions were made and all cycles
of chemotherapy were delivered on schedule with the excep-
tion of one patient in whom cycle 2 was delayed because of
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suspected di ated herpes zoster infection, the diagnosis
of which subsequently proved to be false. On no occasion
was treatment delayed because of myelosuppression. Al-
though myelosuppression was seen, it was characterically
short-lived with a rapid recovery in the absolute neutrophil
count. These data are summarised in Table II. There were no
episodes offebrile neutropenia and no intravenous antibiotics
were used. Anaemia and thrombocytopenia were observed
and both red celi and platelet transfusions had to be
administered on one occasion for one patient with an epis-
taxis. Red cells were transfused on nine occasions (29 units in
total). There was no evidence of cumulative toxicity.
Non-haematological toxicity The amount of nausea and
vomiting seen was quite mild in view of the prophylactic
antiemetics used. Two patients experieced mild drowsiness
and one patient developed transent hallucinations. Bone
pain was exprienced by many patients and its distribution is
described in Table Im. This was, however, minor and re-
sponded promptly to minor analgesics with the exception of
one patient who required admission for severe back pain
which required treatment with opiates but did not recur with
subsequent retreatment with G-CSF. The median cardiac
ejection fraction prior to therapy was 63% (range 53-77%)
as compared with a median of 59% after the fourth cycle of
therapy (range 45-79%, P= 0.009, Wilcoxon signed-rank
test). There were, however, no clinical instances of left ven-
Table I Characteristics of20 patients receivingifosfamnide/epirubicin/
Filgrastim (G-CSF)
n
Median age (range)
Prior hormone therapy
Prior adjuvant chemotherapy
Prior local radiotherapy
Locally advanced
Metastatic
Metastatic sites
Liver
Lung
Bone
SEin
Lymph nodes
Thyroid
Median performance status
(range, ECOG)
20
44 years (23-55)
2
I
8
4
16
3
7
8
2
7
1
l (0-2)
Table H Percentage of WHO grade haematological toxicity in 79
cydes ofifosfamide and epirubicin and Filgastrim (G-CSF)
WHO grade
0 1 2 3 4
Leucopenia 18 19 20 30 13
Granulocytopenia 30 15 14 19 14'
Anaemia 18 25 48 9 0
Thrombocytopenia 80 8 5 5 2
aTwogranukocyte counts were not performed.
Tabk m Non-haematological toxcities in 20 women treated with
ifosfamide/epirubcin/Fidgastrim (G-CSF)
Nom-haatological toxicities n
Alopecia 20 (WHO grade 3)
Hallucinations 1 (WHO grde 2)
Mild drowsiness 2 (WHO grade 2)
Facial flushing 2 (WHO grade 2)
Mucositis 2 (WHO grade 1)
Bone pain (All WHO grade 2)
Chest I
Neck and shoulder 2
Generahsed 6
Sacral/back/knee 9
Head IX c - acsF- ~
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tricular failure. Minor and transient elevations in serum
alkalin phosphatase and lactate dehydrogenase levels were
seen with G-CSF therapy.
These results indicate that the combination ofifosfamide and
epirubicin given at 14 day intervals with G-CSF is a highly
effective regimen for the treatment of metastatic and locally
advanced breast cancer. The high objective resonse rate is
similar to that found in many other studies using intensive
chemotherapy in breast cancer (Antman and Gale, 1988;
Bronchud et al., 1989). The regimen gives as high a response
rate as the aceerated doxorubicin regimen of Bronchud et
al. (1989) but with much less skin and mucosal toxicity than
seen with that regimen. The median duration of remission
was fairly short (1.3-20.1 months), and this probably reflects
the poor overall prognosis of the group. Additionally, it was
clear from the lack of thrombocytopenia experieced that a
further escalation of the epirubicin dose might be possible,
and this has indeed been planned for a further study with the
aim of improving the complete emission rate. In addition to
its usefulness as a 'stand-alone' chemotherapy regin in the
treatment of metastatic disease, this regimen might also be
useful as an induction regimen prior to intensfication with
high-dose chemotherapy and either autologous bone marrow
or peripheral stem cell transplantation as has been used by
other investigators (Dunphy and Spitzer, 1990; 1992; Antman
et al., 1992; Eddy, 1992; Eddy et al., 1992). While the
number of patients treated with locally advanced disease was
small, all of them responded to treatment, maing the use of
this regimen as a neoadjuvant treatment an exciting pos-
sibility. It would be interesting to use this regimen more
extensively in a neoadjuvant manner as such an approach
would appear to be favourable (Scholl et al., 1991). Addi-
tionally, dose int on with an anthracycline-containing
regimen appears to improve survival over low-dose therapy
(Wood et al., 1994).
The toxicity of this regimen was clearly acceptable with no
instances of neutropenic septicemia, thus demonstrating the
efficacy of G-CSF. It is possible that incidence of grade
I/IV neutropenia may have been worse than that actually
seen because blood counts were only taken weekly and thus a
short nadir may have been missed. Even if this was the case,
the ability to deliver full doses on time and the complete lack
of neutropenic sepsis is impressive. While a statistically
significant fall in left ventricular function was observed, the
size of this was small and not thought to be clinically
significant In addition, the entire treatment was complet in
8 weeks with only one delay (which was not due to
myelosuppression), and this shorter duration of therapy
should be preferable to some of the longer lasting regimens
currently in clinical practice for the treatment of metastatic
breast cancr. Other non-haematological toxicities were
generally mild and not dose limitng. These included three
eplsodes ofmild ifosfainde encephalopathy and mild degrees
of bone pain attributable to G-CSF therapy which was easily
controlled by the use of minor analgesics. In addition, tran-
sient rises in serum alkaline phosphatase and lctate dehyd-
rogenase were seen, as has previously been described with
G-CSF therapy.
In conclusion, we have shown that it is possible to deliver
four cycles of ifosfamide 5 gm-2 and epirubicin 60 mgm2
every 14 days with G-CSF with acceptable non-haemato-
logical toxicity and obtain a very high response rate. Analysis
of the haematological toxicity indicates that further escala-
tion of the epirubicin dose may be possible. This regimen
would appear to be ideal as an induction egimen prior to
high-dose consoldation and either autologous bone marrow
or peripheral stem cell transplantation.
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